TEST:

Avantect™

Avantect is a blood test that detects epigenomic and genomic profiles of cell-free DNA (cfDNA) associated with pancreatic cancer. Developed using cutting-edge epigenomic and genomic science as well as machine learning, it provides actionable information to help guide next steps when a cancer signal is detected. The Avantect test has been validated in patients at a high risk for developing pancreatic cancer, including those aged 50 and older who are newly diagnosed with type 2 diabetes. The test’s performance has an overall sensitivity of 66.7% and specificity of 96.9%.